Literature DB >> 11128233

Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery.

R Kitzes-Cohen1, D Farin, G Piva, S Ivry, R Sharony, R Amar, G Uretzky.   

Abstract

Vancomycin concentrations in serum, tissues, and sternum, administered as prophylaxis to patients during coronary artery bypass surgery, were measured. Vancomycin (15 mg/kg) was administered to 15 patients 1 hour before skin incision. Blood, tissue, and sternum samples were collected before, during, and after bypass. The concentration in serum at the end of infusion was 55.1 +/- 22.8 microg/mL, the mean elimination half-life was 9 +/- 4 hours, the areas under the concentration-time curve (AUC) from 0 to 12 hours and from 0 to infinity were 90.6 +/- 25.1 and 289.7 +/- 86.5 microg/h per mL, respectively, the mean residence time (MRT) was 11.9 +/- 5.0 hours, the mean volume of distribution was 51.1 +/- 12.2 L, and the total clearance was 78.3 +/- 32.6 mL/min. Vancomycin concentrations in serum, tissues, and sternum during the operation were greater than the MIC90 for most staphylococci and ranged from 16 to 55 microg/mL in serum and from 4 to 39 microg/g in sternum and tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128233     DOI: 10.1097/00007691-200012000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

Review 1.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

5.  Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.

Authors:  Maria del Mar Fernández de Gatta Garcia; Natalia Revilla; Maria Victoria Calvo; Alfonso Domínguez-Gil; Amparo Sánchez Navarro
Journal:  Intensive Care Med       Date:  2006-12-13       Impact factor: 17.440

Review 6.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia.

Authors:  Silvia Garazzino; Alessandro Aprato; Lorena Baietto; Antonio D'Avolio; Agostino Maiello; Francesco Giuseppe De Rosa; Domenico Aloj; Marco Siccardi; Antonio Biasibetti; Alessandro Massè; Giovanni Di Perri
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling.

Authors:  Xiangqing Song; Meizi Zeng; Yi Wu; Yong Pan
Journal:  Front Microbiol       Date:  2021-04-22       Impact factor: 5.640

9.  Bone and subcutaneous adipose tissue pharmacokinetics of vancomycin in total knee replacement patients.

Authors:  Mats Bue; Mikkel Tøttrup; Pelle Hanberg; Otto Langhoff; Hanne Birke-Sørensen; Theis M Thillemann; Torben L Andersson; Kjeld Søballe
Journal:  Acta Orthop       Date:  2017-09-15       Impact factor: 3.717

10.  Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations.

Authors:  Chie Emoto; Trevor N Johnson; Brooks T McPhail; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.